BTIG Maintains Buy on DexCom, Lowers Price Target to $120
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Marie Thibault maintains a Buy rating on DexCom (NASDAQ:DXCM) but lowers the price target from $156 to $120.
July 26, 2024 | 7:35 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BTIG analyst Marie Thibault maintains a Buy rating on DexCom but lowers the price target from $156 to $120.
The Buy rating suggests continued confidence in DexCom's long-term prospects, but the lowered price target indicates some near-term challenges or adjustments in expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100